Ironwood Pharmaceuticals Company Insiders

IRWD Stock  USD 3.34  0.18  5.11%   
About 72% of Ironwood Pharmaceuticals' corporate insiders are selling. The analysis of the overall insider sentiment regarding Ironwood Pharmaceuticals suggests that many insiders are alarmed. Ironwood Pharmaceuticals employs about 267 people. The company is managed by 16 executives with a total tenure of roughly 20 years, averaging almost 1.0 years of service per executive, having 16.69 employees per reported executive.
Julie McHugh  Director
Independent Director
Thomas McCourt  SVP
Chief Commercial Officer and Sr. VP of Marketing and Sales

Ironwood Pharmaceuticals' Insider Buying Vs Selling

28

 
Selling
 
Buying

Latest Trades

2024-11-18Sravan Kumar EmanyDisposed 11001 @ 4.08View
2024-08-12Minardo JohnDisposed 9910 @ 4.27View
2024-06-10Julie MchughDisposed 22766 @ 6.29View
2024-06-06Catherine MoukheibirDisposed 44426 @ 6.36View
2024-03-06Jon R DuaneAcquired 6920 @ 8.7View
2024-03-04Sravan Kumar EmanyAcquired 10684 @ 9.38View
2024-02-12Thomas A MccourtDisposed 177164 @ 15.24View
Monitoring Ironwood Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Ironwood Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Ironwood Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Ironwood will maintain a workforce of about 270 employees by December 2024.
 
Credit Downgrade
 
Yuan Drop
 
Covid

Ironwood Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of 0.1305 % which means that it generated a profit of $0.1305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7472) %, meaning that it created substantial loss on money invested by shareholders. Ironwood Pharmaceuticals' management efficiency ratios could be used to measure how well Ironwood Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At present, Ironwood Pharmaceuticals' Return On Equity is projected to slightly grow based on the last few years of reporting. At present, Ironwood Pharmaceuticals' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 356.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 3.4 M.
The current year's Net Income Applicable To Common Shares is expected to grow to about 211.4 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 137.1 M.

Ironwood Pharmaceuticals Workforce Comparison

Ironwood Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 8,924. Ironwood Pharmaceuticals holds roughly 267 in number of employees claiming about 2.99% of equities under Health Care industry.

Ironwood Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (0.01) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.28 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.28.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.9964
Way Down
Very volatile

Ironwood Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Ironwood Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Ironwood Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Ironwood Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-09-01
0.5
1
2
 3,282 
 13,017 
2024-06-01
1.125
9
8
 197,060 
 244,921 
2024-03-01
2.0909
23
11
 1,537,806 
 584,474 
2023-12-01
0.6667
2
3
 2,919 
 19,874 
2023-09-01
2.0
4
2
 47,968 
 9,021 
2023-06-01
2.0
10
5
 181,745 
 100,409 
2023-03-01
0.8261
19
23
 1,064,751 
 543,747 
2022-12-01
0.2
1
5
 1,244 
 56,494 
2022-09-01
0.1818
2
11
 19,415 
 213,572 
2022-06-01
0.8571
12
14
 386,966 
 659,266 
2022-03-01
0.6316
12
19
 665,261 
 120,262 
2021-12-01
0.4444
4
9
 89,183 
 168,402 
2021-09-01
1.25
5
4
 103,820 
 10,910 
2021-06-01
3.75
15
4
 339,097 
 27,880 
2021-03-01
1.1579
22
19
 2,991,090 
 88,845 
2020-12-01
0.6
9
15
 183,946 
 227,633 
2020-09-01
0.3333
1
3
 1,600 
 9,214 
2020-06-01
0.4074
11
27
 219,059 
 375,059 
2020-03-01
0.3462
9
26
 576,527 
 341,666 
2019-12-01
0.8333
5
6
 207,020 
 4,834 
2019-09-01
0.3571
5
14
 249,192 
 499,497 
2019-06-01
1.375
44
32
 1,102,981 
 3,486,670 
2019-03-01
0.4595
17
37
 3,047,252 
 3,020,904 
2018-12-01
0.7727
17
22
 6,090,398 
 6,368,689 
2018-09-01
0.8947
17
19
 306,489 
 536,123 
2018-06-01
5.0
10
2
 130,045 
 3,500 
2018-03-01
1.0769
14
13
 1,619,537 
 139,812 
2017-12-01
0.4
4
10
 140,159 
 259,269 
2017-09-01
0.3333
1
3
 153.00 
 3,707 
2017-06-01
2.2
11
5
 190,142 
 133,200 
2017-03-01
0.9
18
20
 1,752,199 
 434,978 
2016-12-01
1.0
5
5
 324,822 
 333,700 
2016-09-01
1.0
2
2
 332.00 
 3,407 
2016-06-01
2.6
13
5
 208,234 
 32,475 
2016-03-01
1.0
17
17
 1,990,478 
 955,505 
2015-12-01
1.0
6
6
 348,569 
 423,733 
2015-09-01
4.0
4
1
 7,934 
 3,725 
2015-03-01
0.8519
23
27
 1,451,490 
 2,853,856 
2014-12-01
0.6429
9
14
 156,803 
 322,164 
2014-09-01
4.5
9
2
 2,225,705 
 65,407 
2014-06-01
1.3846
18
13
 259,192 
 896,914 
2014-03-01
0.7333
22
30
 926,411 
 3,327,497 
2013-12-01
1.8571
13
7
 3,701,748 
 601,080 
2013-09-01
5.5
11
2
 104,727 
 950,000 
2013-06-01
2.8
14
5
 263,976 
 382,434 
2013-03-01
1.3889
25
18
 1,256,501 
 5,061,731 
2012-12-01
1.1053
21
19
 180,196 
 450,566 
2012-09-01
0.2903
9
31
 3,978 
 942,455 
2012-06-01
2.0
8
4
 165,911 
 156,874 
2012-03-01
2.0
10
5
 596,956 
 1,343,656 
2011-12-01
3.0
12
4
 84,233 
 197,174 
2011-09-01
5.0
10
2
 69,797 
 66,666 
2011-06-01
1.1111
10
9
 61,674 
 644,400 
2011-03-01
0.9286
13
14
 181,953 
 165,621 
2010-03-01
0.1579
3
19
 20,366 
 10,617,262 

Ironwood Pharmaceuticals Notable Stakeholders

An Ironwood Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ironwood Pharmaceuticals often face trade-offs trying to please all of them. Ironwood Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ironwood Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Thomas McCourtChief Commercial Officer and Sr. VP of Marketing and SalesProfile
Julie McHughIndependent DirectorProfile
Matt RoacheDirector RelationsProfile
MPH MDVP DevelopmentProfile
MBA MSVP OperationsProfile
Jana NoeldekeBasel LeaderProfile
Ronald SilverCorporate OfficerProfile
Marcel MoulaisonVice OperationsProfile
Beth CalitriHead RelationsProfile
Sravan EmanyPrincipal VPProfile
Jason RickardVP COOProfile
Mike NanfitoVice ExcellenceProfile
John MinardoChief VPProfile
Michael MDSenior OfficerProfile
Greg MartiniVice RelationsProfile
Andrew DavisSenior OfficerProfile

About Ironwood Pharmaceuticals Management Performance

The success or failure of an entity such as Ironwood Pharmaceuticals often depends on how effective the management is. Ironwood Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ironwood management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ironwood management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.14)(2.04)
Return On Capital Employed 1.07  1.13 
Return On Assets(2.13)(2.02)
Return On Equity 2.89  3.04 
Please note, the presentation of Ironwood Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ironwood Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ironwood Pharmaceuticals' management manipulating its earnings.

Ironwood Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Ironwood Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ironwood Pharmaceuticals within its industry.

Ironwood Pharmaceuticals Manpower Efficiency

Return on Ironwood Pharmaceuticals Manpower

Revenue Per Employee1.7M
Revenue Per Executive27.7M
Net Loss Per Employee3.8M
Net Loss Per Executive62.6M

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Global Correlations
Find global opportunities by holding instruments from different markets
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Fundamental Analysis
View fundamental data based on most recent published financial statements